Research programme: CNS disorders therapeutics - AMRI/Bristol-Myers Squibb

Drug Profile

Research programme: CNS disorders therapeutics - AMRI/Bristol-Myers Squibb

Latest Information Update: 11 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Albany Molecular Research Inc
  • Developer AMRI; Bristol-Myers Squibb
  • Class
  • Mechanism of Action Biogenic amine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders

Most Recent Events

  • 07 Nov 2013 Discontinued - Preclinical for CNS disorders in USA (unspecified route)
  • 27 May 2009 AMRI and Bristol-Myers Squibb continue to evaluate additional compounds in their ongoing research collaboration for CNS disorders
  • 27 May 2009 Bristol-Myers Squibb files a CTA with the MPA in Sweden to initiate phase I trials with a second biogenic amine reuptake inhibitor for CNS disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top